These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16720240)

  • 1. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors.
    Hanaoka H; Mukai T; Tamamura H; Mori T; Ishino S; Ogawa K; Iida Y; Doi R; Fujii N; Saji H
    Nucl Med Biol; 2006 May; 33(4):489-94. PubMed ID: 16720240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors.
    Hanaoka H; Mukai T; Habashita S; Asano D; Ogawa K; Kuroda Y; Akizawa H; Iida Y; Endo K; Saga T; Saji H
    Nucl Med Biol; 2007 Jul; 34(5):503-10. PubMed ID: 17591550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
    Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
    J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.
    Zhang K; An R; Gao Z; Zhang Y; Aruva MR
    Nucl Med Biol; 2006 May; 33(4):505-12. PubMed ID: 16720242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide.
    Kuhnast B; Bodenstein C; Haubner R; Wester HJ; Senekowitsch-Schmidtke R; Schwaiger M; Weber WA
    Nucl Med Biol; 2004 Apr; 31(3):337-44. PubMed ID: 15028246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
    Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
    J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
    Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
    Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
    Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
    Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
    J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
    Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
    Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
    Sabbah EN; Kadouche J; Ellison D; Finucane C; Decaudin D; Mather SJ
    Nucl Med Biol; 2007 Apr; 34(3):293-304. PubMed ID: 17383579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
    Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of a
    Mikaeili A; Erfani M; Sabzevari O
    Nucl Med Biol; 2017 Nov; 54():10-17. PubMed ID: 28810154
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.